Suppr超能文献

阿霉素的新兴研究与未来方向:概述

Emerging Research and Future Directions on Doxorubicin: A Snapshot.

作者信息

Sinha Saket Jitendre, Kumar Bhupinder, Prasad Chandra Prakash, Chauhan Shyam Singh, Kumar Manish

机构信息

All India Institute of Medical Sciences, Department of Biochemistry, Bathinda, India.

All India Institute of Medical Sciences, Department of Medicine, Bilaspur, India.

出版信息

Asian Pac J Cancer Prev. 2025 Jan 1;26(1):5-15. doi: 10.31557/APJCP.2025.26.1.5.

Abstract

Doxorubicin, a widely used anthracycline antibiotic, has been a cornerstone in cancer chemotherapy since the 1960s. In addition to doxorubicin, anthracycline chemotherapy medications include daunorubicin, idarubicin, and epirubicin. For many years, doxorubicin has been the chemotherapy drug of choice for treating a broad variety of cancers. Despite its efficacy, doxorubicin therapy is hindered by serious side effects, primarily cardiotoxicity, and the challenges of drug resistance. Recent research has focused on optimizing doxorubicin's therapeutic index by developing cardioprotective strategies, such as dexrazoxane, and utilizing non-invasive monitoring techniques to reduce cardiac risk. To counteract drug resistance, innovative formulations like nanoparticle-based delivery systems, enhance targeted drug delivery and overcome cellular resistance mechanisms. Furthermore, using combination approaches involving immunotherapy, photodynamic therapy, and genetic modulation, offer promising synergies to maximize tumor eradication. Personalized approaches, supported by pharmacogenomics and predictive biomarkers, are enhancing individualized treatment regimens, aiming to increase effectiveness and minimize toxicity. Future research on doxorubicin focuses on developing advanced drug delivery systems, such as nanoparticle and liposomal formulations, to enhance targeted delivery, minimize systemic toxicity, and improve therapeutic precision. Efforts are also underway to design combination therapies that integrate doxorubicin with immunotherapies, photodynamic approaches, and gene-based treatments, aiming to overcome resistance and increase tumor-specific effects. These advancements signify a transition toward more personalized and effective doxorubicin-based cancer therapies, prioritizing reduced side effects and improved patient outcomes. This article focusses on the ongoing innovations aimed at maximizing the therapeutic potential of doxorubicin while addressing its limitations.

摘要

阿霉素是一种广泛使用的蒽环类抗生素,自20世纪60年代以来一直是癌症化疗的基石。除阿霉素外,蒽环类化疗药物还包括柔红霉素、伊达比星和表柔比星。多年来,阿霉素一直是治疗多种癌症的首选化疗药物。尽管其疗效显著,但阿霉素治疗受到严重副作用的阻碍,主要是心脏毒性以及耐药性问题。最近的研究集中在通过开发心脏保护策略(如右丙亚胺)和利用非侵入性监测技术来降低心脏风险,以优化阿霉素的治疗指数。为了对抗耐药性,基于纳米颗粒的递送系统等创新制剂可增强靶向药物递送并克服细胞耐药机制。此外,采用免疫疗法、光动力疗法和基因调节等联合方法可产生有前景的协同作用,以最大限度地根除肿瘤。由药物基因组学和预测性生物标志物支持的个性化方法正在加强个体化治疗方案,旨在提高疗效并将毒性降至最低。关于阿霉素的未来研究集中在开发先进的药物递送系统,如纳米颗粒和脂质体制剂,以增强靶向递送、将全身毒性降至最低并提高治疗精度。还在努力设计将阿霉素与免疫疗法、光动力方法和基于基因的治疗相结合的联合疗法,旨在克服耐药性并增强肿瘤特异性效应。这些进展标志着向更个性化、更有效的基于阿霉素的癌症治疗的转变,优先考虑减少副作用和改善患者预后。本文重点关注旨在最大限度发挥阿霉素治疗潜力同时解决其局限性的 ongoing innovations。 (注:原文中“ongoing innovations”直译为“正在进行的创新”,这里可能表述不太准确,可根据上下文进一步优化表述,但按照要求未做修改)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9418/12082430/5563b6e4184d/APJCP-26-5-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验